دورية أكاديمية
أعرض في EDS

T cell costimulation, checkpoint inhibitors and anti-tumor therapy.

التفاصيل البيبلوغرافية
العنوان: T cell costimulation, checkpoint inhibitors and anti-tumor therapy.
المؤلفون: Nandi D; Department of Biochemistry, Indian Institute of Science, Bengaluru 560 012, India., Pathak S, Verma T, Singh M, Chattopadhyay A, Thakur S, Raghavan A, Gokhroo A, Vijayamahantesh
المصدر: Journal of biosciences [J Biosci] 2020; Vol. 45.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer India, in co-publication with Indian Academy of Sciences Country of Publication: India NLM ID: 8100809 Publication Model: Print Cited Medium: Internet ISSN: 0973-7138 (Electronic) Linking ISSN: 02505991 NLM ISO Abbreviation: J Biosci Subsets: MEDLINE
أسماء مطبوعة: Publication: <2006- >: New Delhi : Springer India, in co-publication with Indian Academy of Sciences
Original Publication: [Bangalore] : Indian Academy of Sciences, 1979-
مواضيع طبية MeSH: Costimulatory and Inhibitory T-Cell Receptors/*physiology , Immune Checkpoint Inhibitors/*pharmacology , Immune Checkpoint Inhibitors/*therapeutic use , Neoplasms/*drug therapy , T-Lymphocytes/*immunology, Antigen-Presenting Cells/immunology ; CD28 Antigens/chemistry ; CD28 Antigens/metabolism ; CTLA-4 Antigen/chemistry ; CTLA-4 Antigen/metabolism ; Costimulatory and Inhibitory T-Cell Receptors/chemistry ; Costimulatory and Inhibitory T-Cell Receptors/genetics ; Humans ; Lymphocyte Activation ; Programmed Cell Death 1 Receptor/metabolism ; Receptors, Antigen, T-Cell/physiology
مستخلص: The hallmarks of the adaptive immune response are specificity and memory. The cellular response is mediated by T cells which express cell surface T cell receptors (TCRs) that recognize peptide antigens in complex with major histocompatibility complex (MHC) molecules on antigen presenting cells (APCs). However, binding of cognate TCRs with MHC-peptide complexes alone (signal 1) does not trigger optimal T cell activation. In addition to signal 1, the binding of positive and negative costimulatory receptors to their ligands modulates T cell activation. This complex signaling network prevents aberrant activation of T cells. CD28 is the main positive costimulatory receptor on naı¨ve T cells; upon activation, CTLA4 is induced but reduces T cell activation. Further studies led to the identification of additional negative costimulatory receptors known as checkpoints, e.g. PD1. This review chronicles the basic studies in T cell costimulation that led to the discovery of checkpoint inhibitors, i.e. antibodies to negative costimulatory receptors (e.g. CTLA4 and PD1) which reduce tumor growth. This discovery has been recognized with the award of the 2018 Nobel prize in Physiology/Medicine. This review highlights the structural and functional roles of costimulatory receptors, the mechanisms by which checkpoint inhibitors work, the challenges encountered and future prospects.
References: Immunity. 2002 Jan;16(1):23-35. (PMID: 11825563)
J Thorac Oncol. 2016 Dec;11(12):2238-2240. (PMID: 27423391)
J Biol Chem. 1995 Sep 8;270(36):21181-7. (PMID: 7545666)
Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236)
J Immunol. 2008 Oct 1;181(7):4832-9. (PMID: 18802087)
Br J Pharmacol. 2010 Oct;161(3):512-26. (PMID: 20880392)
Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a002436. (PMID: 20534709)
Int J Mol Sci. 2018 Mar 03;19(3):. (PMID: 29510522)
Nat Immunol. 2011 Jun;12(6):492-9. (PMID: 21739672)
Nat Immunol. 2005 Mar;6(3):271-9. (PMID: 15696168)
Nature. 1988 Sep 29;335(6189):443-5. (PMID: 2458531)
Diabetes. 2017 Feb;66(2):437-447. (PMID: 28108610)
Genomics. 1994 Oct;23(3):704-6. (PMID: 7851902)
Immunity. 2016 May 17;44(5):973-88. (PMID: 27192564)
J Immunol. 1992 Jul 15;149(2):380-8. (PMID: 1320641)
Clin Cancer Res. 2009 Jan 1;15(1):390-9. (PMID: 19118070)
Eur J Immunol. 2002 Mar;32(3):634-43. (PMID: 11857337)
Am Health Drug Benefits. 2015 Aug;8(Spec Issue):9. (PMID: 26380599)
Aust J Exp Biol Med Sci. 1975 Feb;53(1):27-42. (PMID: 238498)
Immunity. 1997 Mar;6(3):327-39. (PMID: 9075933)
Nat Rev Endocrinol. 2017 Apr;13(4):195-207. (PMID: 28106152)
Nat Rev Immunol. 2011 Nov 25;11(12):852-63. (PMID: 22116087)
Int Immunol. 1998 Oct;10(10):1563-72. (PMID: 9796923)
Immunity. 2011 Sep 23;35(3):400-12. (PMID: 21943489)
Int J Mol Sci. 2019 May 24;20(10):. (PMID: 31137683)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
J Immunol. 1997 Jun 1;158(11):5091-4. (PMID: 9164923)
Immunity. 1995 Nov;3(5):541-7. (PMID: 7584144)
J Immunol. 1999 Feb 1;162(3):1270-7. (PMID: 9973379)
Immunol Rev. 2009 May;229(1):244-58. (PMID: 19426226)
Clin Cancer Res. 2019 Feb 1;25(3):989-999. (PMID: 30206165)
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11695-700. (PMID: 16864790)
J Leukoc Biol. 2018 Jan;103(1):23-33. (PMID: 29345058)
Proc Natl Acad Sci U S A. 1989 Feb;86(4):1333-7. (PMID: 2465550)
Sci Adv. 2019 Feb 20;5(2):eaav2437. (PMID: 30801016)
J Exp Med. 2004 Mar 15;199(6):831-42. (PMID: 15007096)
Cancer Res. 2013 Apr 15;73(8):2435-44. (PMID: 23423978)
Ann Rheum Dis. 2008 Apr;67(4):547-54. (PMID: 17921185)
J Exp Med. 1999 Jan 18;189(2):435-40. (PMID: 9892625)
J Immunol. 2003 Feb 1;170(3):1257-66. (PMID: 12538684)
J Immunol. 1999 Aug 1;163(3):1128-31. (PMID: 10415006)
EMBO Mol Med. 2011 Oct;3(10):581-92. (PMID: 21739608)
Medicine (Baltimore). 2017 Sep;96(35):e7805. (PMID: 28858091)
Nat Med. 2000 Feb;6(2):211-4. (PMID: 10655112)
Eur J Immunol. 2007 Nov;37 Suppl 1:S83-93. (PMID: 17972349)
Infect Immun. 1999 Aug;67(8):3786-92. (PMID: 10417139)
Biochemistry. 1974 Jan 15;13(2):211-22. (PMID: 4358939)
Nat Immunol. 2008 Apr;9(4):335-7. (PMID: 18349808)
Cancer Immunol Res. 2013 Jul;1(1):32-42. (PMID: 24777248)
Annu Rev Immunol. 2008;26:677-704. (PMID: 18173375)
J Immunol. 2002 Nov 15;169(10):5538-45. (PMID: 12421930)
Nat Med. 2014 Dec;20(12):1410-1416. (PMID: 25329329)
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. (PMID: 12218188)
J Exp Med. 2005 Dec 19;202(12):1643-8. (PMID: 16352741)
Cancer Immunol Immunother. 2013 Jun;62(6):1021-8. (PMID: 23591982)
Structure. 2017 Aug 1;25(8):1163-1174. (PMID: 28768162)
J Immunol. 2010 Aug 1;185(3):1375-8. (PMID: 20601598)
J Immunol. 2000 Apr 1;164(7):3554-62. (PMID: 10725710)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
J Exp Med. 2001 Apr 2;193(7):839-46. (PMID: 11283156)
J Biol Chem. 1999 Jun 25;274(26):18470-6. (PMID: 10373455)
J Immunol. 2010 May 15;184(10):5466-5474. (PMID: 20375308)
Nat Immunol. 2011 Dec 11;13(2):188-95. (PMID: 22157630)
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18607-12. (PMID: 18000051)
Cell. 2017 Sep 7;170(6):1120-1133.e17. (PMID: 28803728)
Immunity. 1997 Dec;7(6):885-95. (PMID: 9430233)
Crit Rev Immunol. 2017;37(2-6):371-420. (PMID: 29773027)
Nature. 2001 Mar 29;410(6828):608-11. (PMID: 11279502)
Immunity. 2001 Dec;15(6):935-45. (PMID: 11754815)
Immunol Rev. 2009 May;229(1):12-26. (PMID: 19426212)
Cancer Res. 2012 Oct 15;72(20):5209-18. (PMID: 22915761)
Trends Immunol. 2019 Jan;40(1):12-21. (PMID: 30545676)
Front Oncol. 2015 Jun 08;5:117. (PMID: 26106583)
J Immunol. 2002 Feb 15;168(4):2046-53. (PMID: 11823542)
J Exp Med. 1992 Dec 1;176(6):1595-604. (PMID: 1334116)
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9273-8. (PMID: 9256472)
J Virol. 2006 Nov;80(22):11398-403. (PMID: 16956940)
PLoS One. 2013 Dec 02;8(12):e82203. (PMID: 24312642)
Int Immunol. 2013 Dec;25(12):671-81. (PMID: 24048955)
Onco Targets Ther. 2016 Aug 12;9:5023-39. (PMID: 27574444)
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8. (PMID: 2513569)
N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127)
Int Immunol. 2002 Jun;14(6):555-66. (PMID: 12039907)
Front Immunol. 2016 Aug 10;7:304. (PMID: 27559335)
Immunity. 1994 Aug;1(5):405-13. (PMID: 7882171)
Proc Natl Acad Sci U S A. 1987 Dec;84(23):8573-7. (PMID: 2825196)
EMBO J. 1992 Nov;11(11):3887-95. (PMID: 1396582)
J Exp Med. 2014 Apr 7;211(4):715-25. (PMID: 24687957)
Eur J Cancer. 2016 Feb;54:139-148. (PMID: 26765102)
Nat Commun. 2018 Mar 14;9(1):1080. (PMID: 29540686)
Science. 2000 Oct 27;290(5492):816-9. (PMID: 11052947)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
Immunity. 2019 Jan 15;50(1):195-211.e10. (PMID: 30635237)
Nature. 1992 Apr 16;356(6370):607-9. (PMID: 1313950)
Ann N Y Acad Sci. 2013 Jul;1291:1-13. (PMID: 23772560)
Immunity. 1995 Jul;3(1):87-98. (PMID: 7621080)
Lancet Oncol. 2017 Dec;18(12):e731-e741. (PMID: 29208439)
J Exp Med. 1987 Feb 1;165(2):302-19. (PMID: 3029267)
Front Immunol. 2019 Mar 29;10:630. (PMID: 31001256)
Immunity. 1999 Aug;11(2):141-51. (PMID: 10485649)
Mol Immunol. 2009 Jan;46(3):457-72. (PMID: 19081138)
Blood. 2008 Aug 15;112(4):1175-83. (PMID: 18523152)
J Biol Chem. 2002 Mar 8;277(10):7766-75. (PMID: 11726649)
Science. 1992 Aug 7;257(5071):792-5. (PMID: 1496399)
Mol Cell Biol. 1998 Jan;18(1):644-54. (PMID: 9418910)
J Immunol. 2002 Sep 1;169(5):2323-9. (PMID: 12193697)
J Immunol. 2013 Dec 1;191(11):5542-50. (PMID: 24154626)
Diseases. 2018 May 19;6(2):. (PMID: 29783736)
Eur J Immunol. 2004 Nov;34(11):2996-3005. (PMID: 15468055)
Nature. 2015 Jan 8;517(7533):214-8. (PMID: 25317561)
Science. 1995 Nov 10;270(5238):985-8. (PMID: 7481803)
Science. 1993 Jan 15;259(5093):368-70. (PMID: 7678351)
Front Immunol. 2019 Jul 23;10:1544. (PMID: 31396201)
Cell. 2000 Sep 1;102(5):553-63. (PMID: 11007474)
J Immunol. 2014 Apr 15;192(8):3465-9. (PMID: 24639356)
Arthritis Rheum. 2010 Oct;62(10):3077-87. (PMID: 20533545)
Cancer Res. 2015 Feb 1;75(3):508-518. (PMID: 25480946)
Immunol Rev. 2009 May;229(1):356-86. (PMID: 19426233)
Science. 2008 Oct 10;322(5899):271-5. (PMID: 18845758)
Immunity. 2004 Mar;20(3):337-47. (PMID: 15030777)
N Engl J Med. 2000 Nov 2;343(18):1313-24. (PMID: 11058677)
Immunity. 2019 Jan 15;50(1):181-194.e6. (PMID: 30635236)
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515. (PMID: 30395287)
Immunity. 1994 Sep;1(6):501-8. (PMID: 7534617)
J Clin Invest. 2019 Jan 2;129(1):349-363. (PMID: 30530991)
Sci Rep. 2016 May 24;6:26210. (PMID: 27217330)
J Immunol. 2008 Aug 1;181(3):1806-13. (PMID: 18641318)
Mol Cell Biol. 1987 Dec;7(12):4472-81. (PMID: 2830495)
Cell. 2015 Apr 9;161(2):205-14. (PMID: 25860605)
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1610-5. (PMID: 17242367)
N Engl J Med. 2016 Nov 10;375(19):1845-1855. (PMID: 27717298)
Neurology. 2008 Sep 16;71(12):917-24. (PMID: 18794494)
Mol Biol Evol. 2011 Oct;28(10):2731-9. (PMID: 21546353)
J Immunol. 1995 Jun 1;154(11):5757-68. (PMID: 7751626)
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917. (PMID: 29581255)
J Immunol. 2000 May 15;164(10):5015-8. (PMID: 10799854)
Blood. 2018 Jan 4;131(1):58-67. (PMID: 29118008)
Oncotarget. 2017 Jun 27;8(26):41841-41853. (PMID: 28611299)
J Rheumatol. 2006 Nov;33(11):2162-6. (PMID: 17014006)
Oncotarget. 2017 Jun 13;8(24):39198-39208. (PMID: 28487496)
Cancer Biomark. 2018 Feb 6;21(2):287-297. (PMID: 29171986)
Infect Immun. 2018 May 22;86(6):. (PMID: 29610255)
Nature. 2001 Mar 29;410(6828):604-8. (PMID: 11279501)
J Immunol. 1994 Feb 15;152(4):1618-28. (PMID: 7907103)
J Immunol. 2013 Jan 1;190(1):211-9. (PMID: 23209326)
Cancer Immunol Res. 2014 Sep;2(9):846-56. (PMID: 24872026)
Sci Transl Med. 2019 Jan 16;11(475):. (PMID: 30651320)
BMC Med. 2015 Sep 04;13:211. (PMID: 26337719)
Nature. 2009 Mar 12;458(7235):206-10. (PMID: 19078956)
Clin Cancer Res. 2017 Oct 15;23(20):6165-6177. (PMID: 28855348)
Transplantation. 2001 Mar 27;71(6):801-11. (PMID: 11330546)
J Immunol. 2006 May 15;176(10):5725-9. (PMID: 16670276)
Biosci Rep. 2017 Dec 12;37(6):. (PMID: 29089469)
Immunity. 2018 Aug 21;49(2):264-274.e4. (PMID: 30076099)
J Young Pharm. 2010 Jul;2(3):332-6. (PMID: 21042496)
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. (PMID: 28351930)
J Exp Med. 1995 Aug 1;182(2):459-65. (PMID: 7543139)
Immunity. 2002 Aug;17(2):201-10. (PMID: 12196291)
J Immunol. 1999 Sep 1;163(5):2634-9. (PMID: 10453003)
PLoS Pathog. 2016 Nov 1;12(11):e1005909. (PMID: 27802341)
Science. 2014 Sep 26;345(6204):1623-1627. (PMID: 25213377)
J Exp Med. 2003 May 5;197(9):1083-91. (PMID: 12719480)
Eur J Biochem. 1984 Jul 2;142(1):153-60. (PMID: 6235110)
Drugs. 2017 Jul;77(11):1221-1233. (PMID: 28608166)
Nat Immunol. 2014 May;15(5):465-72. (PMID: 24705298)
J Immunol. 1991 Oct 15;147(8):2461-6. (PMID: 1717561)
J Immunol. 2001 Apr 15;166(8):4943-8. (PMID: 11290772)
Immunity. 2002 Jun;16(6):769-77. (PMID: 12121659)
J Immunol. 2004 Jun 1;172(11):6735-43. (PMID: 15153490)
Protein Sci. 1994 Nov;3(11):2148-50. (PMID: 7535614)
J Leukoc Biol. 2002 Nov;72(5):921-31. (PMID: 12429713)
Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13402-7. (PMID: 20624978)
EBioMedicine. 2017 Mar;17:30-44. (PMID: 28233730)
Eur J Cancer. 2017 Mar;74:55-72. (PMID: 28335888)
Cell. 1982 Mar;28(3):499-506. (PMID: 6804095)
Nature. 1987 May 7-13;327(6117):64-7. (PMID: 3106825)
Immunity. 2004 May;20(5):563-75. (PMID: 15142525)
Science. 2015 Nov 27;350(6264):1084-9. (PMID: 26541606)
Biol Blood Marrow Transplant. 2013 Nov;19(11):1638-49. (PMID: 24047754)
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243)
Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. (PMID: 29549159)
Nat Immunol. 2020 Feb;21(2):178-185. (PMID: 31959982)
Cancer Res. 2011 Aug 15;71(16):5445-54. (PMID: 21708958)
Lancet Oncol. 2018 Jun;19(6):737-746. (PMID: 29778737)
Science. 2015 Jul 24;349(6246):436-40. (PMID: 26206937)
J Immunol. 2010 Sep 1;185(5):3007-18. (PMID: 20656923)
Mol Cell Biol. 2005 Nov;25(21):9543-53. (PMID: 16227604)
Genome Biol. 2005;6(6):223. (PMID: 15960813)
Cancer Immunol Immunother. 2007 May;56(5):739-45. (PMID: 17195077)
Front Pharmacol. 2018 Sep 20;9:1050. (PMID: 30294272)
Eur J Immunol. 1998 Mar;28(3):926-35. (PMID: 9541588)
Nat Biotechnol. 2005 Sep;23(9):1117-25. (PMID: 16151405)
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4223-E4232. (PMID: 28484017)
J Exp Med. 1996 Aug 1;184(2):783-8. (PMID: 8760834)
Mol Cell Biol. 2009 Jul;29(13):3710-21. (PMID: 19398586)
Mucosal Immunol. 2013 Mar;6(2):324-34. (PMID: 22910217)
Nat Rev Immunol. 2018 Feb;18(2):91-104. (PMID: 28990586)
DNA Cell Biol. 2010 Jul;29(7):381-6. (PMID: 20380573)
Folia Histochem Cytobiol. 2011;49(1):49-54. (PMID: 21526489)
J Immunol. 1996 Jun 15;156(12):4576-81. (PMID: 8648099)
J Immunol. 2009 May 15;182(10):5891-7. (PMID: 19414738)
Science. 1970 Sep 11;169(3950):1042-9. (PMID: 4194660)
J Exp Med. 2002 Aug 5;196(3):335-48. (PMID: 12163562)
Nature. 1987 Jul 16-22;328(6127):267-70. (PMID: 3496540)
J Immunol. 1982 Nov;129(5):2293-300. (PMID: 6181166)
Annu Rev Pathol. 2013 Jan 24;8:477-512. (PMID: 23157335)
Cell. 1981 Feb;23(2):357-68. (PMID: 6781756)
Annu Rev Immunol. 2001;19:225-52. (PMID: 11244036)
J Clin Invest. 1999 May;103(9):1243-52. (PMID: 10225967)
Adv Exp Med Biol. 1991;292:63-9. (PMID: 1835264)
Science. 2015 Nov 27;350(6264):1079-84. (PMID: 26541610)
Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494)
Immunogenetics. 1990;31(3):198-201. (PMID: 2156778)
BioDrugs. 2018 Oct;32(5):481-497. (PMID: 30168070)
Immunology. 2009 Mar;126(3):363-77. (PMID: 18710402)
Nat Med. 1999 Dec;5(12):1365-9. (PMID: 10581077)
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9196-201. (PMID: 21576466)
J Immunother Cancer. 2018 Nov 23;6(1):128. (PMID: 30470252)
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):524-9. (PMID: 25548162)
J Exp Med. 1994 Mar 1;179(3):819-30. (PMID: 7509361)
Int J Cancer. 2018 Jul 1;143(1):45-51. (PMID: 29424425)
Infect Immun. 2015 May;83(5):2011-7. (PMID: 25733520)
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2586-91. (PMID: 12606712)
Genes Dis. 2016 Dec;3(4):252-256. (PMID: 29623291)
Immunity. 1997 May;6(5):583-9. (PMID: 9175836)
Immunol Cell Biol. 2017 Oct;95(9):775-788. (PMID: 28611475)
Parasite Immunol. 2004 Jan;26(1):19-28. (PMID: 15198642)
Crit Rev Immunol. 2009;29(3):187-201. (PMID: 19538134)
J Clin Invest. 2016 Jan;126(1):3-4. (PMID: 26727227)
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. (PMID: 31028147)
N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407)
Lancet Oncol. 2018 Mar;19(3):310-322. (PMID: 29449192)
Immunotargets Ther. 2015 May 28;4:111-22. (PMID: 27471717)
J Exp Med. 1991 Sep 1;174(3):561-9. (PMID: 1714933)
J Immunol. 1998 Mar 1;160(5):2223-30. (PMID: 9498761)
Cell Host Microbe. 2015 May 13;17(5):628-41. (PMID: 25891357)
J Immunol. 1999 May 15;162(10):5784-91. (PMID: 10229811)
J Immunol. 2006 Apr 1;176(7):4191-200. (PMID: 16547256)
Immunity. 2004 Mar;20(3):327-36. (PMID: 15030776)
Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527)
J Clin Invest. 2019 Feb 1;129(2):518-530. (PMID: 30422820)
Immunity. 1996 Jun;4(6):535-43. (PMID: 8673700)
J Immunol. 2011 Mar 1;186(5):2772-9. (PMID: 21263073)
Immunity. 2014 Nov 20;41(5):802-14. (PMID: 25464856)
Immunity. 1997 Mar;6(3):303-13. (PMID: 9075931)
Int J Cancer. 2012 Feb 15;130(4):865-75. (PMID: 21455983)
J Exp Med. 1991 Mar 1;173(3):721-30. (PMID: 1847722)
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92. (PMID: 18818309)
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22699-22709. (PMID: 31636208)
Immunology. 2009 Sep;128(1 Suppl):e471-8. (PMID: 19191906)
J Transl Med. 2009 May 20;7:35. (PMID: 19457253)
J Immunol. 2000 May 15;164(10):5319-27. (PMID: 10799894)
Science. 2011 Apr 29;332(6029):600-3. (PMID: 21474713)
Sci Rep. 2017 Mar 23;7:45124. (PMID: 28332580)
J Neuroimmunol. 2015 Nov 15;288:79-86. (PMID: 26531698)
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6. (PMID: 23420197)
Science. 1998 Dec 18;282(5397):2263-6. (PMID: 9856951)
Front Immunol. 2018 Aug 31;9:1995. (PMID: 30233588)
J Clin Invest. 2016 Sep 1;126(9):3447-52. (PMID: 27525433)
Immunogenetics. 2001 Aug;53(6):447-54. (PMID: 11685455)
J Immunol. 2004 Dec 15;173(12):7135-9. (PMID: 15585834)
Cell. 2016 Oct 6;167(2):397-404.e9. (PMID: 27667683)
Immunity. 2000 Jan;12(1):51-60. (PMID: 10661405)
Expert Opin Investig Drugs. 2000 Sep;9(9):2147-57. (PMID: 11060799)
Immunity. 2019 Apr 16;50(4):1084-1098.e10. (PMID: 30926234)
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13756-61. (PMID: 17702861)
Immunol Rev. 2005 Apr;204:102-15. (PMID: 15790353)
J Immunol. 2002 Nov 1;169(9):4882-8. (PMID: 12391199)
Trends Immunol. 2003 Jun;24(6):314-9. (PMID: 12810107)
Science. 1996 Mar 22;271(5256):1734-6. (PMID: 8596936)
المشرفين على المادة: 0 (CD28 Antigens)
0 (CTLA-4 Antigen)
0 (Costimulatory and Inhibitory T-Cell Receptors)
0 (Immune Checkpoint Inhibitors)
0 (Programmed Cell Death 1 Receptor)
0 (Receptors, Antigen, T-Cell)
تواريخ الأحداث: Date Created: 20200430 Date Completed: 20210113 Latest Revision: 20210217
رمز التحديث: 20240628
PMID: 32345776
قاعدة البيانات: MEDLINE
الوصف
تدمد:0973-7138